Bioequivalence Study of Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddy's Laboratories Limited Under Fed Condition
Primary Purpose
FED
Status
Completed
Phase
Phase 1
Locations
India
Study Type
Interventional
Intervention
Pantoprazole Sodium
Sponsored by
About this trial
This is an interventional treatment trial for FED
Eligibility Criteria
Inclusion Criteria:
- Subjects will provide written informed consent.
- Subjects must be healthy human beings within 18-45 years of age (inclusive) weighing at least 50 kg.
- Subjects must be within ±10% of ideal body weight in relation to height according to Life Insurance Corporation of India height-weight chart for non-medical cases.
- Subjects must be of normal health as determined by medical history and physical examination performed within 15 days prior to the commencement of the study.
- Have normal EcG, X-ray and vital signs.
- Availability of subject for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent.
If subject is a female volunteer and
- Is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.
- is postmenopausal for at least 1 year.
- is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)
Exclusion Criteria:
- Subjects incapable of understanding the informed consent.
- Subjects with BP≤90/60 or BP≥140/90
- History of hypersensitivity or idiosyncratic reaction to pantoprazole or other proton pump inhibitors.
- Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function.
- Regular smoker who smokes more than ten cigarettes daily and has difficulty in abstaining from smoking for the duration of each study period.
- Subjects who has taken over the counter or prescribed medications, including any enzyme modifying drugs or any systemic medication within the past 30 days prior to start of clinical period.
- History of any psychiatric illness, which may impair the ability to provide written, informed consent.
- Subjects who have a history of alcohol or substance abuse within the last 5 years.
- Subjects with clinically significant abnormal values of laboratory parameters.
- Subjects who have participated in any other clinical investigation using experimental drug or had bled more than 350 mL in the past 3 months.
- Subjects with positive urine screen for drugs of abuse.
- Any subject in whom pantoprazole is contraindicated for medical reasons.
- Female volunteers demonstrating a positive pregnancy screen.
- Female volunteers who are currently breast-feeding.
Sites / Locations
- VimtaLabsLtd.
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Pantoprazole Sodium
Protonix
Arm Description
Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddys Laboratories Limited
Protonix 40 mg DR Tablets of Wyeth Laboratories
Outcomes
Primary Outcome Measures
Bioequivalence on Cmax and AUC parameters
Secondary Outcome Measures
Full Information
NCT ID
NCT01283932
First Posted
January 25, 2011
Last Updated
January 25, 2011
Sponsor
Dr. Reddy's Laboratories Limited
1. Study Identification
Unique Protocol Identification Number
NCT01283932
Brief Title
Bioequivalence Study of Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddy's Laboratories Limited Under Fed Condition
Official Title
A Randomized, Two-treatment, Two-period, Two-sequence,Single Dose, Crossover Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets (Dr. Reddy's Laboratories Ltd, India) to be Compared With Protonix® 40 mg (Pantoprazole Sodium) Delayed Release Tablets (Wyeth Laboratories, USA) in Healthy, Adult, Human Subjects Under Fed Conditions.
Study Type
Interventional
2. Study Status
Record Verification Date
January 2011
Overall Recruitment Status
Completed
Study Start Date
October 2004 (undefined)
Primary Completion Date
December 2004 (Actual)
Study Completion Date
December 2004 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Dr. Reddy's Laboratories Limited
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To compare the single dose bioavailability of pantoprazole sodium 40 mg delayed release tablets (Dr. Reddy's Laboratories Ltd, India) with Protonix® 40 mg delayed release tablets (Wyeth Laboratories, USA) in 52 (+ 6 standby) healthy, adult, human subjects under fasting conditions.
Detailed Description
This is a Open label, balanced, randomized two-treatment, two-period,two-sequence, crossover bioequivalence study with at least 07 days washout period between each drug administration under fed conditions.52 (+6 standby) healthy, adult, human subjects were enrolled. A single oral dose of 40 mg of pantoprazole delayed release tablet will be administered along with 240 mL of drinking water within 30 minutes after serving a high fat breakfast.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
FED
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
52 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Pantoprazole Sodium
Arm Type
Experimental
Arm Description
Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddys Laboratories Limited
Arm Title
Protonix
Arm Type
Active Comparator
Arm Description
Protonix 40 mg DR Tablets of Wyeth Laboratories
Intervention Type
Drug
Intervention Name(s)
Pantoprazole Sodium
Other Intervention Name(s)
Protonix DR Tablets 40 mg
Intervention Description
Pantoprazole Sodium DR Tablets 40 mg
Primary Outcome Measure Information:
Title
Bioequivalence on Cmax and AUC parameters
Time Frame
2 months
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Subjects will provide written informed consent.
Subjects must be healthy human beings within 18-45 years of age (inclusive) weighing at least 50 kg.
Subjects must be within ±10% of ideal body weight in relation to height according to Life Insurance Corporation of India height-weight chart for non-medical cases.
Subjects must be of normal health as determined by medical history and physical examination performed within 15 days prior to the commencement of the study.
Have normal EcG, X-ray and vital signs.
Availability of subject for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent.
If subject is a female volunteer and
Is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.
is postmenopausal for at least 1 year.
is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)
Exclusion Criteria:
Subjects incapable of understanding the informed consent.
Subjects with BP≤90/60 or BP≥140/90
History of hypersensitivity or idiosyncratic reaction to pantoprazole or other proton pump inhibitors.
Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function.
Regular smoker who smokes more than ten cigarettes daily and has difficulty in abstaining from smoking for the duration of each study period.
Subjects who has taken over the counter or prescribed medications, including any enzyme modifying drugs or any systemic medication within the past 30 days prior to start of clinical period.
History of any psychiatric illness, which may impair the ability to provide written, informed consent.
Subjects who have a history of alcohol or substance abuse within the last 5 years.
Subjects with clinically significant abnormal values of laboratory parameters.
Subjects who have participated in any other clinical investigation using experimental drug or had bled more than 350 mL in the past 3 months.
Subjects with positive urine screen for drugs of abuse.
Any subject in whom pantoprazole is contraindicated for medical reasons.
Female volunteers demonstrating a positive pregnancy screen.
Female volunteers who are currently breast-feeding.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mangesh Kulkarni, M.D
Organizational Affiliation
VimtaLabsLtd.
Official's Role
Principal Investigator
Facility Information:
Facility Name
VimtaLabsLtd.
City
Hyderabad
State/Province
Andhrapradesh
ZIP/Postal Code
500 051
Country
India
12. IPD Sharing Statement
Learn more about this trial
Bioequivalence Study of Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddy's Laboratories Limited Under Fed Condition
We'll reach out to this number within 24 hrs